This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key FDA Action Dates

Allos Therapeutics (ALTH)
Drug/indication: Pralatrexate for peripheral T-cell lymphoma
FDA decision date: Sept. 24

Allos expects the FDA to convene an advisory panel meeting to review pralatrexate, although a meeting has not been formally announced. The scheduling of the advisory meeting may delay the FDA's approval decision.

Amgen (AMGN)
Drug/indication: Denosumab for osteoporosis
FDA advisory panel date: Aug. 13
FDA decision date: Oct. 19

Denosumab is the most important drug in the company's late-stage pipeline. Approval for osteoporosis, and later for certain cancer indications, could re-invigorate earnings growth after a couple of flat years. Denosumab's safety profile will be the focus of the Aug. 13 advisory panel meeting.

Acorda Therapeutics (ACOR - Get Report)
Drug/indication: Fampridine for multiple sclerosis
FDA decision date: Oct. 22

Fampridine improves nerve function and is being developed to improve the walking abilities of patients with multiple sclerosis.

Drug/indication: Acapodene for prostate cancer
FDA decision date: Oct. 30

Acapodene is designed to reduce bone fractures in prostate cancer patients being treated with androgen deprivation therapy.

Transcept Pharmaceuticals (TSPT)
Drug/indication: Intermezzo for insomnia
FDA decision date: Oct. 30

Intermezzo is a dissolvable, low-dose form of the sleep aid Ambien which will be marketed for people who awake in the middle of the night but can't fall back to sleep.

Cadence Pharmaceuticals (CADX)
Drug/indication: Acetevance for acute pain/fever
FDA decision date: Nov. 13

Acetevance is an injectable form of the painkiller acetaminophen for use in hospitals.

Somaxon Pharmaceuticals (SOMX)
Drug/indication: Silenor for insomnia
FDA decision date: Dec. 4

The FDA refused to approve Silenor last February, requesting additional clinical information from Somaxon. The company resubmitted Silenor in June.
3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CADX $0.00 0.00%
CTIC $1.62 4.20%
ACOR $29.92 0.71%
AUXL $36.47 -0.16%
TSPT $30.00 0.67%


Chart of I:DJI
DOW 16,912.29 +122.10 0.73%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,791.1520 +42.7910 0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs